Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04826185 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

A Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Imbria Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
67
Enrollment target
14
Study locations

NCT04826185: Completed Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Imbria Pharmaceuticals.

NCT04826185 is a Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy that has completed, run by Imbria Pharmaceuticals. The registered enrollment target is 67 participants, below the 241-participant average among 3 other Non-obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (72% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04826185, a Phase 2 study of Non-obstructive Hypertrophic Cardiomyopathy, has completed, sponsored by Imbria Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
67 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Conditions Studied

Non-obstructive Hypertrophic Cardiomyopathy

Interventions

  • DRUG Placebo
  • DRUG IMB-1018972

Study Locations (14)

California

  • Imbria Investigational Site - La Jolla
  • Imbria Investigational Site - Los Angeles
  • Imbria Investigational Site - San Francisco

Massachusetts

  • Imbria Investigational Site - Boston
  • Imbria Investigational Site - Burlington

Illinois

  • Imbria Investigational Site - Chicago

Missouri

  • Imbria Investigational Site - St Louis

New Jersey

  • Imbria Investigational Site - Morristown

New York

  • Imbria Investigational Site - New York

North Carolina

  • Imbria Investigational Site - Charlotte

Oregon

  • Imbria Investigational Site - Portland

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2021-06-14
Est. Completion 2023-09-18
Phase Phase 2
Imbria Pharmaceuticals

2 total trials

What the finished NCT04826185 record still lists

NCT04826185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 241-participant average among 3 other Non-obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Non-obstructive Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04826185 lists 14 locations in 11 states (California, Massachusetts, Illinois).

Frequently Asked Questions

What is clinical trial NCT04826185 about?

NCT04826185 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial". The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

What is the current status of trial NCT04826185?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2021-06-14. Estimated completion is 2023-09-18.

What conditions does trial NCT04826185 study?

This clinical trial studies the following conditions: Non-obstructive Hypertrophic Cardiomyopathy.

What interventions are being tested in trial NCT04826185?

The interventions under investigation include: Placebo (DRUG), IMB-1018972 (DRUG).

Who is sponsoring clinical trial NCT04826185?

This trial is sponsored by Imbria Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04826185 being conducted?

This trial has 14 study locations across California, Illinois, Massachusetts, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-obstructive Hypertrophic Cardiomyopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04826185, the US trial registry maintained by the National Library of Medicine. NCT04826185 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.